Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial
- PMID: 32163106
- PMCID: PMC7068666
- DOI: 10.1001/jamaoncol.2020.0007
Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial
Abstract
Importance: The GeparOcto randomized clinical trial compared the efficacy of 2 neoadjuvant breast cancer (BC) treatment regimens: sequential intense dose-dense epirubicin, paclitaxel, and cyclophosphamide (iddEPC) vs weekly paclitaxel and nonpegylated liposomal doxorubicin (PM) in patients with different biological BC subtypes. Patients with triple-negative BC (TNBC) randomized to the PM arm received additional carboplatin (PMCb). Overall, no difference in pathologic complete response (pCR) rates was observed between study arms. It remained elusive whether the germline variant status of BRCA1/2 and further BC predisposition genes are associated with treatment outcome.
Objective: To determine treatment outcome for BC according to germline variant status.
Design, setting, and participants: This retrospective biomarker study is a secondary analysis of the GeparOcto multicenter prospective randomized clinical trial conducted between December 2014 and June 2016. Genetic analyses assessing for variants in BRCA1/2 and 16 other BC predisposition genes in 914 of 945 women were performed at the Center for Familial Breast and Ovarian Cancer, Cologne, Germany, from August 2017 through December 2018.
Main outcomes and measures: Proportion of patients who achieved pCR (ypT0/is ypN0 definition) after neoadjuvant treatment according to germline variant status.
Results: In the study sample of 914 women with different BC subtypes with a mean (range) age at BC diagnosis of 48 (21-76) years, overall higher pCR rates were observed in patients with BRCA1/2 variants than in patients without (60.4% vs 46.7%; odds ratio [OR], 1.74; 95% CI, 1.13-2.68; P = .01); variants in non-BRCA1/2 BC predisposition genes were not associated with therapy response. Patients with TNBC with BRCA1/2 variants achieved highest pCR rates. In the TNBC subgroup, a positive BRCA1/2 variant status was associated with therapy response in both the PMCb arm (74.3% vs 47.0% without BRCA1/2 variant; OR, 3.26; 95% CI, 1.44-7.39; P = .005) and the iddEPC arm (64.7% vs 45.0%; OR, 2.24; 95% CI, 1.04-4.84; P = .04). A positive BRCA1/2 variant status was also associated with elevated pCR rates in patients with ERBB2-negative, hormone receptor-positive BC (31.8% vs 11.9%; OR, 3.44; 95% CI, 1.22-9.72; P = .02).
Conclusions and relevance: Effective chemotherapy for BRCA1/2-mutated TNBC is commonly suggested to be platinum based. With a pCR rate of 64.7%, iddEPC may also be effective in these patients, though further prospective studies are needed. The elevated pCR rate in BRCA1/2-mutated ERBB2-negative, hormone receptor-positive BC suggests that germline BRCA1/2 testing should be considered prior to treatment start.
Trial registration: ClinicalTrials.gov Identifier: NCT02125344.
Conflict of interest statement
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7068666/bin/jamaoncol-6-744-g001.gif)
![Figure 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7068666/bin/jamaoncol-6-744-g002.gif)
Similar articles
-
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.Eur J Cancer. 2022 Jan;160:100-111. doi: 10.1016/j.ejca.2021.10.011. Epub 2021 Nov 17. Eur J Cancer. 2022. PMID: 34801353 Clinical Trial.
-
Management of early breast cancer in patients bearing germline BRCA mutations.Semin Oncol. 2020 Oct;47(5):243-248. doi: 10.1053/j.seminoncol.2020.07.006. Epub 2020 Aug 18. Semin Oncol. 2020. PMID: 32912765 Review.
-
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.Eur J Cancer. 2019 Jan;106:181-192. doi: 10.1016/j.ejca.2018.10.015. Epub 2018 Dec 5. Eur J Cancer. 2019. PMID: 30528802 Clinical Trial.
-
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.JAMA Oncol. 2017 Oct 1;3(10):1378-1385. doi: 10.1001/jamaoncol.2017.1007. JAMA Oncol. 2017. PMID: 28715532 Free PMC article. Clinical Trial.
-
Germline Mutations in Triple-Negative Breast Cancer.Breast Care (Basel). 2017 Mar;12(1):15-19. doi: 10.1159/000455999. Epub 2017 Feb 24. Breast Care (Basel). 2017. PMID: 28611536 Free PMC article. Review.
Cited by
-
Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response.Explor Target Antitumor Ther. 2024;5(1):232-250. doi: 10.37349/etat.2024.00215. Epub 2024 Feb 28. Explor Target Antitumor Ther. 2024. PMID: 38464390 Free PMC article. Review.
-
The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy.Breast Cancer Res Treat. 2024 Jun;205(2):241-248. doi: 10.1007/s10549-024-07247-4. Epub 2024 Feb 12. Breast Cancer Res Treat. 2024. PMID: 38345692 Free PMC article.
-
The Role of Mesenchymal Stem Cells in Modulating the Breast Cancer Microenvironment.Cell Transplant. 2023 Jan-Dec;32:9636897231220073. doi: 10.1177/09636897231220073. Cell Transplant. 2023. PMID: 38135917 Free PMC article. Review.
-
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.Breast Cancer Res Treat. 2024 Apr;204(2):237-248. doi: 10.1007/s10549-023-07165-x. Epub 2023 Dec 19. Breast Cancer Res Treat. 2024. PMID: 38112922 Free PMC article. Clinical Trial.
-
Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.Ann Surg Oncol. 2023 Dec;30(13):8412-8418. doi: 10.1245/s10434-023-14319-0. Epub 2023 Oct 5. Ann Surg Oncol. 2023. PMID: 37798552
References
-
- Schneeweiss A, Möbus V, Tesch H, et al. . Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): a randomised phase III trial. Eur J Cancer. 2019;106:181-192. doi:10.1016/j.ejca.2018.10.015 - DOI - PubMed
-
- Hahnen E, Lederer B, Hauke J, et al. . Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol. 2017;3(10):1378-1385. doi:10.1001/jamaoncol.2017.1007 - DOI - PMC - PubMed
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous